Summary
Other Scenarios:
- RDY - NVS
- RDY - TEVA
- NVS - WPI
- TEVA - WPI
| Buyer: | Dr. Reddy's Laboratories Limited (ADR) (RDY) | Last Price: | 39.10 | Market Cap.: | 6.60B |
|---|---|---|---|---|---|
| Target: | Watson Pharmaceuticals, Inc. (WPI) | Last Price: | 51.61 | Market Cap.: | 6.47B |
Lines of Business Summary:
- Dr. Reddy's Laboratories Limited (ADR) (RDY) competes in 1 industry and 115 product/service groups
- Watson Pharmaceuticals, Inc. (WPI) competes in 1 industry and 256 product/service groups
- A combined entity will have 13% Product/Service Group overlap
- Dr. Reddy's Laboratories Limited (ADR) (RDY) has 0 and Watson Pharmaceuticals, Inc. (WPI) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
785 |
Biopharmaceuticals |
|
|
347 |
|
Healthcare Services |
|
139 | |
|
Outsourced Biomedical Services |
|
|
41 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 77)
|
Target (Total: 250)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 6)
|
Target (Total: 14)
|
Buyer (Total: 3)
|
Target (Total: 6)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 13,455 | 5,830 |
| Revenue Per Employee | 123,969.4 | 607,083.5 |
| Total Revenue | 420.0 | 882.4 |
| Total Expenses | 347.6 | 848.0 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
195.8 | 484.6 |
|
SG&A Expense
|
128.2 | 241.6 |
|
Research & Development
|
28.5 | 75.8 |
|
Other Operating Expense
|
-4.9 | 0.1 |
|
Operating Income
|
72.4 | 34.4 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
n/a | 26.53 |
|
Fwd P/E
|
27.06 | 15.15 |
|
Fwd P/Rev
|
3.80 | 1.83 |
| Book Value | n/a | 3,218.0 |
|
Curr Portion of LTD/Cap Lease
|
n/a | 35.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Dr. Reddy's Laboratories Limited (Dr. Reddy?s) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment. Its Global Generics segment includes branded and unbranded prescription and over-the-counter (OTC) drug products business. Its Pharmaceutical Services and Active Ingredients (PSAI) segment consists of its active pharmaceutical ingredients (API) business and its custom pharmaceutical services business. Effective July 1, 2009, the Company?s drug discovery operations at Hyderabad, India were absorbed into Aurigene Discovery Technologies Limited (Aurigene), one of the Company?s wholly owned subsidiary. The Company also closed its discovery research facility in Atlanta, Georgia in the United States of America.
Target
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates manufacturing, distribution, research and development (R&D), and administrative facilities in the United States of America. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2009, the Company marketed approximately 170 generic pharmaceutical product families and 30 brand pharmaceutical product families and distributed approximately 8,000 stock-keeping units (SKUs) through its Distribution business in the United States. On December 2, 2009, Watson completed the acquisition of Robin Hood Holdings Limited and Cobalt Laboratories, Inc. On November 26, 2009, the Company acquired Arrow Group. Watson also acquired a 36% ownership interest in Eden Biopharm Group (Eden).
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
52.48 | 42.69 |
|
Operating Margin %
|
2.75 | 10.31 |
|
Quick Ratio
|
n/a | 1.05 |
|
Current Ratio
|
n/a | 2.34 |
|
Coverage Ratio
|
-0.14 | -0.13 |
| Total Assets | n/a | 5,847.7 |
| Return on Equity % | n/a | 6.93 |
| Return on Assets % | n/a | 3.81 |
|
Cash+ ST Inv. Per Share
|
n/a | 2.14 |
| Total Debt | 0.0 | 1,197.1 |
| Total Debt to Equity % | n/a | 37.2 |
| Total Debt to Tangible Equity % | n/a | n/a |
|
Debt to Asset %
|
n/a | 20.47 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors
The Distributors Subsector is comprised of companies that distribute a wide variety of healthcare products, equipment and supplies to healthcare service providers and institutions.
|
|
|
|
Healthcare Support Services
The Support Services Subsector is comprised of companies that provide non-medical services for managing, enhancing, facilitating, and enabling the healthcare delivery process.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat irreversible damage to the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
Target Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Alpha Blockers/Beta Blockers
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
Target Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Target Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Target Products:
|
|
|
|
Stroke |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that prevent strokes by blocking the influx of calcium ions into vascular cells.
Target Products:
|
|
|
|
Tremors |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Estrogens/Progestins
Therapeutics that treat acne by providing estrogen and progestin.
Target Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Buyer Products:
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dermatitis |
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Irritable Bowel Syndrome (IBS) |
|
|
|
Anticholinergic Agents
Therapeutics that treat irritable bowel syndrome by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Alpha-Glucosidase Inhibitors
Therapeutics that treat diabetes by stopping the enzyme that releases glucose from larger molecules.
Target Products:
|
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Buyer Products:
Target Products:
|
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
Target Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat gouty arthritis by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Crystalization Inhibitors
Therapeutics that treat gouty arthritis by preventing the deposition of urate crystals in the joints.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys and prevent the precipitation of urate in the joint.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increasing levels of high-density lipoproteins.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Target Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Target Products:
|
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Iron Supplements
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by iron deficiency by replacing missing iron.
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increasing
levels of high-density lipoproteins.
Target Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that bind blood phosphorous.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat hyperuricemia by preventing the conversion of hypoxanthine to uric acid.
Target Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Hormonal
Therapeutics that treat systemic lupus with hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Heliobacter pylori |
|
|
|
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Periodontitis |
|
|
|
Tetracyclines
Therapeutics that treat bacterial infections of the gums, teeth, and underlying bone by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting an enzyme vital to bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Pneumonia |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Target Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Target Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pharynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
Target Products:
|
|
|
|
Papillomavirus |
|
|
|
Genital Warts |
|
|
|
Podophyllins
Therapeutics that treat viral infections that cause genital warts by eroding skin lesions.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
Target Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
Target Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Crystalization Inhibitors
Therapeutics that treat gouty arthritis by preventing the deposition of urate crystals in the joints.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Target Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Buyer Products:
Target Products:
|
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Buyer Products:
Target Products:
|
|
|
|
Dementia |
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat dementia by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat complex partial seizures by decreasing excitability of neurons.
Buyer Products:
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat simple partial seizures by decreasing excitability of neurons.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Barbiturates
Therapeutics that treat tonic clonic seizures by acting as sedatives through nonselective suppression of central nervous system activities.
Buyer Products:
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Headaches |
|
|
|
Tension Type |
|
|
|
Barbiturates/Analgesics/Antipyretics/Opioids/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons, decreasing pain by inhibiting the production of prostaglandins as well as stimulating the opioid receptors.
Target Products:
|
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons and decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Motion Sickness |
|
|
|
Anticholinergic Agents
Therapeutics that treat motion sickness by selectively deterring actions of the involuntary nervous system.
Target Products:
|
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Target Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Target Products:
|
|
|
|
Carbamate Derivatives
Therapeutics that treat anxiety by blocking the NMDA receptor thus blocking the effects of excitatory amino acids and suppressing seizure activity.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat anxiety by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Target Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat bipolar disorders by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Depression |
|
|
|
Monoaminergic Antagonists
Therapeutics that treat depression by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
Target Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
Target Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Buyer Products:
Target Products:
|
|
|
|
Sleep Disorders |
|
|
|
Excessive Daytime Sleepiness (EDS) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat excessive daytime sleepiness (EDS) by stimulating the adrenergic receptors, which cause nervous system stimulation.
Target Products:
|
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
Target Products:
|
|
|
|
Melatonin Receptor Agonists
Therapeutics that treat insomnia by stimulating the release of melatonin which regulates the circadian rhythms and sleep cycle.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Selective Progesterone Receptor Modulators (SERM)
Therapeutics that prevent conception by binding progesterone receptors.
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Target Products:
|
|
|
|
Progestins
Therapeutics that treat female disorders characterized by the inability to achieve pregnancy or carry a pregnancy to term by increasing progesterone level in the body to induce uteran conditions favorable to conception and pregnancy.
Target Products:
|
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Target Products:
|
|
|
|
Sexual Dysfunction |
|
|
|
Androgens
Therapeutics that treat female sexual dysfunction by providing male sex hormone, such as testosterone, that is important for the normal functioning of the female reproductive system.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy for lymphoma characterized by the presence of Reed-Sternberg cells by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Target Products:
|
|
|
|
Gonadotropin Releasing Hormone (GnRH) Antagonists
Therapeutics that treat and manage primary tumors of the prostate gland by blocking the action of gonadotropin releasing hormone and thus decreasing levels of testosterone.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Target Products:
|
|
|
|
Glaucoma |
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Barbiturates/Analgesics/Antipyretics/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutic combinations that treat pain by depressing neural activity, preventing inflammation and fever, and stimulating the central nervous system.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Leukotriene Receptor Antagonists
Therapeutics that treat asthma by reducing inflammation in the lung passages by working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Anticholinergic Agents
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine and by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Amphetamines
Therapeutics that treat coughs and colds by helping to relieve nasal congestion.
Target Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Target Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Target Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
|
Restlessness/Apprehension |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat the nervousness which precedes surgery by increasing the action of gamma aminobutyric acid at the relevant neuroreceptors.
Target Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that increase the concentration of several neurotransmitters in the brain by inhibiting their uptake.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
Target Products:
|
|
|
|
Testicular |
|
|
|
Failure |
|
|
|
Hormonal Treatments |
|
|
|
Androgens
Therapeutics that treat testicular failure by providing male sex hormones.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat COPD by blocking the action of choline and other cholinergic agents from binding to the muscarinic receptor.
Target Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that treat abnormal levels of phosphate in the blood by binding to excess phosphate groups.
Target Products:
|
|
|
|
Nephrolithiasis/Renal Calculi (Kidney Stones) |
|
|
|
Calcium |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat the formation of kidney stones from calcium deposits by reducing uric acid formation through the inhibition of xanthine oxidase.
Target Products:
|
|
|
|
Uric Acid |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the conversion of hypoxanthine to uric acid, thus preventing the deposition of excess uric acid in the kidneys.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Target Products:
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors |
|
|
|
Pharmaceuticals Distributors |
|
|
|
Specialty/Generic
Specialty drug distributors focus on the distribution of specific drugs. Because specialty drug distributors typically target certain therapeutic areas, in addition to distributing only certain classes of drugs, these companies will provide complementary services to the targeted patient populations. Examples of such complementary services include disease management programs, drug therapies (such as infusion therapy), and other disease class-specific services.
Target Products:
|
|
|
|
Healthcare Support Services |
|
|
|
Consulting
Services providing advice, assistance, and information to a wide range of healthcare companies, including pharmaceutical, medical devices, and health services companies.
Target Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Development/Manufacturing Services |
|
|
|
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.
Target Products:
|
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Biopharmaceutical OEM |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Novartis AG (ADR)
|
|
n/a | 134,491.104 | 13.54 | 11.43 | 2.68 | 2.64 | 129.07 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 48,606.480 | 16.54 | 11.47 | 3.13 | 3.00 | 222.97 | |
|
Cardinal Health, Inc.
|
|
n/a | 13,508.249 | 13.85 | 15.13 | 0.14 | 0.13 | 5.77 | |
|
Mylan Inc.
|
|
n/a | 9,313.682 | 41.37 | 13.25 | 1.74 | 1.69 | n/a | |
|
Perrigo Company
|
|
n/a | 6,182.445 | 26.24 | 18.53 | 2.60 | 2.30 | n/a | |
| Buyer | |||||||||
|
Novartis AG (ADR)
|
|
n/a | 134,491.104 | 13.54 | 11.43 | 2.68 | 2.64 | 129.07 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,311.971 | 13.81 | 11.15 | 2.73 | 2.59 | n/a | |
| Target | |||||||||
|
Novartis AG (ADR)
|
|
n/a | 134,491.104 | 13.54 | 11.43 | 2.68 | 2.64 | 129.07 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 48,606.480 | 16.54 | 11.47 | 3.13 | 3.00 | 222.97 | |
|
Covidien plc
|
|
n/a | 23,016.389 | 14.10 | 12.96 | 2.21 | 2.03 | n/a | |
|
Allergan, Inc.
|
|
n/a | 21,511.640 | n/a | 22.42 | 4.45 | 4.46 | 15.52 | |
|
McKesson Corporation
|
|
n/a | 17,413.265 | 13.41 | 14.27 | 0.16 | 0.16 | 5.56 | |
|
Cardinal Health, Inc.
|
|
n/a | 13,508.249 | 13.85 | 15.13 | 0.14 | 0.13 | 5.77 | |
|
Mylan Inc.
|
|
n/a | 9,313.682 | 41.37 | 13.25 | 1.74 | 1.69 | n/a | |
|
AmerisourceBergen Corp.
|
|
n/a | 9,169.217 | 14.40 | 13.73 | 0.12 | 0.11 | 3.10 | |
|
Dr. Reddy's Laboratories Limited (ADR)
|
|
n/a | 6,601.855 | 228.38 | 27.06 | 4.36 | 3.80 | n/a | |
|
Perrigo Company
|
|
n/a | 6,182.445 | 26.24 | 18.53 | 2.60 | 2.30 | n/a | |
|
Endo Pharmaceuticals
|
|
n/a | 4,023.702 | 12.82 | 10.80 | 2.52 | 2.48 | 9.67 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 1,364.366 | 15.88 | 13.02 | 1.27 | 1.40 | 3.16 | |
|
Impax Laboratories, Inc.
|
|
n/a | 1,323.388 | 4.79 | 7.18 | 1.38 | 1.92 | 2.89 | |
|
Auxilium Pharmaceuticals, Inc.
|
|
n/a | 1,087.411 | n/a | -19.90 | 5.50 | 4.96 | 10.49 | |
|
Eurand N.V.
|
|
n/a | 564.754 | n/a | 69.41 | 3.13 | 2.90 | 5.03 | |
|
AMAG Pharmaceuticals, Inc.
|
|
n/a | 368.269 | n/a | -4.34 | 5.92 | 5.49 | 1.41 | |
|
DepoMed, Inc.
|
|
n/a | 304.341 | n/a | -194.67 | 4.16 | 3.81 | 14.90 | |
|
Pain Therapeutics, Inc.
|
|
n/a | 282.019 | n/a | -60.18 | 22.51 | 17.79 | 2.54 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Merck & Co., Inc.
|
|
n/a | 112,390.539 | 14.25 | 10.93 | 2.56 | 2.50 | 713.14 | |
|
The Dow Chemical Company
|
|
n/a | 39,406.308 | 24.16 | 18.47 | 0.75 | 0.76 | 12.01 | |
|
Codexis, Inc.
|
|
n/a | 344.637 | n/a | -26.94 | 3.39 | 3.23 | 3.44 | |
|
Antares Pharma, Inc.
|
|
n/a | 138.233 | n/a | -20.86 | 11.41 | 9.41 | 26.94 | |
|
SCOLR Pharma Inc.
|
|
n/a | 14.447 | n/a | n/a | 18.47 | n/a | 4.50 | |
|
Intelligroup, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Johnson & Johnson
|
|
n/a | 171,750.725 | 12.63 | 13.14 | 2.75 | 2.76 | 6.91 | |
|
Novartis AG (ADR)
|
|
n/a | 134,491.104 | 13.54 | 11.43 | 2.68 | 2.64 | 129.07 | |
|
Mylan Inc.
|
|
n/a | 9,313.682 | 41.37 | 13.25 | 1.74 | 1.69 | n/a | |
|
Warner Chilcott Plc
|
|
n/a | 5,695.310 | 39.00 | 6.38 | 1.92 | 1.92 | n/a | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,511.232 | n/a | -12.19 | 3.02 | 2.93 | n/a | |
|
Crucell N.V. (ADR)
|
|
n/a | 2,553.942 | n/a | -90.00 | 5.55 | 5.38 | 2.92 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 830.450 | n/a | -8.51 | 211.37 | 199.12 | 125.67 | |
|
DepoMed, Inc.
|
|
n/a | 304.341 | n/a | -194.67 | 4.16 | 3.81 | 14.90 | |
|
GeneraMedix, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Daiichi Sankyo Company, Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gedeon Richter Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Amphastar Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Kissei Pharmaceuticals Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Natco Pharma Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 1,364.366 | 15.88 | 13.02 | 1.27 | 1.40 | 3.16 | |
|
Zogenix, Inc.
|
|
n/a | 198.026 | n/a | n/a | 13.53 | n/a | n/a | |
|
National Medical Centre (NMC UAE)
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Walgreen Company
|
|
13.00% | 34,939.783 | 16.71 | 15.15 | 0.52 | 0.49 | 2.79 | |
|
McKesson Corporation
|
|
11.00% | 17,413.265 | 13.41 | 14.27 | 0.16 | 0.16 | 5.56 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 84,154.666 | 10.70 | 6.93 | 1.96 | 2.00 | n/a | |
|
Paladin Labs Inc.
|
|
n/a | 185.507 | 26.37 | n/a | 2.97 | n/a | 1.25 | |
|
Takeda Pharmaceutical Company Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Merck & Co., Inc.
|
|
n/a | 112,390.539 | 14.25 | 10.93 | 2.56 | 2.50 | 713.14 | |
|
The Dow Chemical Company
|
|
n/a | 39,406.308 | 24.16 | 18.47 | 0.75 | 0.76 | 12.01 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 1,364.366 | 15.88 | 13.02 | 1.27 | 1.40 | 3.16 | |
|
Zogenix, Inc.
|
|
n/a | 198.026 | n/a | n/a | 13.53 | n/a | n/a | |
| Target | |||||||||
|
Johnson & Johnson
|
|
n/a | 171,750.725 | 12.63 | 13.14 | 2.75 | 2.76 | 6.91 | |
|
Novartis AG (ADR)
|
|
n/a | 134,491.104 | 13.54 | 11.43 | 2.68 | 2.64 | 129.07 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 84,154.666 | 10.70 | 6.93 | 1.96 | 2.00 | n/a | |
|
Warner Chilcott Plc
|
|
n/a | 5,695.310 | 39.00 | 6.38 | 1.92 | 1.92 | n/a | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,511.232 | n/a | -12.19 | 3.02 | 2.93 | n/a | |
|
Salix Pharmaceuticals, Ltd.
|
|
n/a | 2,710.895 | n/a | 150.87 | 9.39 | 8.01 | 12.71 | |
|
Crucell N.V. (ADR)
|
|
n/a | 2,553.942 | n/a | -90.00 | 5.55 | 5.38 | 2.92 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 830.450 | n/a | -8.51 | 211.37 | 199.12 | 125.67 | |
|
DepoMed, Inc.
|
|
n/a | 304.341 | n/a | -194.67 | 4.16 | 3.81 | 14.90 | |
|
Paladin Labs Inc.
|
|
n/a | 185.507 | 26.37 | n/a | 2.97 | n/a | 1.25 | |
|
Columbia Laboratories Inc.
|
|
n/a | 173.722 | n/a | -6.00 | 4.42 | 4.81 | n/a | |
|
Natco Pharma Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
GeneraMedix, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cipla Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
moksha8 Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Daiichi Sankyo Company, Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gedeon Richter Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Kissei Pharmaceuticals Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Shionogi & Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Amphastar Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Takeda Pharmaceutical Company Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 1,515.5 | 3,399.9 | 4,915.4 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 1,515.5 | 3,399.9 | 4,915.4 |
|
Cost of Revenue
|
720.1 | 1,948.6 | 2,668.7 |
|
SG&A Expense
|
476.3 | 687.2 | 1,163.5 |
|
Depreciation & Amortization
|
14.1 | 154.5 | 168.6 |
|
Research & Development
|
89.9 | 257.6 | 347.5 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
-17.8 | 1.2 | -16.6 |
|
Unusual Expense (Income)
|
191.1 | 0.2 | 191.3 |
| Total Expenses | 1,473.8 | 3,049.3 | 4,523.1 |
|
Operating Income
|
41.6 | 350.6 | 392.2 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-5.7 | -44.1 | -49.8 |
|
Other, Net
|
0.0 | 1.7 | 1.7 |
| Income Before Taxes | 36.1 | 308.2 | 344.3 |
| Income Taxes | 7.2 | 85.2 | 92.4 |
| Income After Taxes | 28.9 | 223.0 | 251.9 |
|
Net Income - Excl. Xord. Items
|
28.9 | 223.0 | 251.9 |
|
Net Income - Incl. Xord. Items
|
28.9 | 223.0 | 251.9 |
|
Income Avail. to Common
|
28.9 | 223.0 | 251.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
169.6 | 122.6 | 292.2 |
|
Basic EPS - Excl. Xord. Items
|
0.17 | 1.82 | 0.86 |
|
Basic EPS - Incl. Xord. Items
|
0.17 | 1.82 | 0.86 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 169.6 | 124.3 | 293.9 |
|
F.D. EPS - Excl. Xord. Items
|
0.17 | 1.79 | 0.86 |
|
F.D. EPS - Incl. Xord. Items
|
0.17 | 1.79 | 0.86 |
| Dividends Per Common Share | 0.24 | 0.00 | 0.24 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
n/a | 255.6 | 255.6 |
|
ST Investments
|
n/a | 10.3 | 10.3 |
|
Accounts Receivable
|
n/a | 523.1 | 523.1 |
|
Inventory
|
n/a | 673.1 | 673.1 |
|
Prepayments and Advances
|
n/a | 159.9 | 159.9 |
|
Other Current Assets
|
n/a | 142.2 | 142.2 |
|
Current Assets
|
n/a | 1,764.2 | 1,764.2 |
|
Accum D&A
|
n/a | 0.0 | 0.0 |
|
PPE, Net
|
n/a | 648.9 | 648.9 |
| Goodwill & Intangibles | n/a | 3,218.4 | 3,218.4 |
| Long Term Investments | n/a | 47.9 | 47.9 |
| Other Assets | n/a | 0.0 | 0.0 |
|
Other LT Assets
|
n/a | 168.3 | 168.3 |
| Total Assets | n/a | 5,847.7 | 5,847.7 |
| Liabilities | |||
| Accounts Payable | n/a | 0.0 | 0.0 |
| Payable/Accrued | n/a | 625.0 | 625.0 |
|
ST Debt
|
n/a | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
n/a | 35.0 | 35.0 |
| Other (Current) Liabilities | n/a | 93.7 | 93.7 |
|
Current Liab.
|
n/a | 753.7 | 753.7 |
|
LT Debt
|
n/a | 1,162.1 | 1,162.1 |
|
Total LT Debt
|
n/a | 1,162.1 | 1,162.1 |
| Minority Interest (BS) | n/a | 1.6 | 1.6 |
| Deferred Taxes | n/a | 454.0 | 454.0 |
|
Other LT Liab.
|
n/a | 258.3 | 258.3 |
|
Total Liabilities
|
n/a | 2,629.7 | 2,629.7 |
| Shareholders Equity | |||
| Common Stock | n/a | 0.4 | 0.4 |
| Additional Paid in Capital | n/a | 1,739.4 | 1,739.4 |
| Retained Earnings | n/a | 1,806.2 | 1,806.2 |
| Treasure Stock | n/a | -311.9 | -311.9 |
| Other Equity | n/a | -16.1 | -16.1 |
|
Total Equity
|
n/a | 3,218.0 | 3,218.0 |
|
Total Liab. & Equity
|
n/a | 5,847.7 | 5,847.7 |
|
Shares Outstanding
|
n/a | 125.1 | 125.1 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | n/a | 223.0 | 223.0 |
| CF Depreciation | n/a | 183.4 | 183.4 |
| CF Amortization | n/a | 72.4 | 72.4 |
| CF Deferred Taxes | n/a | -103.1 | -103.1 |
| Other Non-Cash Items | n/a | 59.2 | 59.2 |
| Change in Working Capital | n/a | 28.9 | 28.9 |
| Total Cash From Operating Activities | n/a | 463.8 | 463.8 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | n/a | -53.4 | -53.4 |
| Other Investing Cash Flows | n/a | -947.8 | -947.8 |
| Total Cash From Investing Activities | n/a | -1,001.2 | -1,001.2 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | n/a | 0.0 | 0.0 |
| Purchase Or Sale of Stock | n/a | 38.3 | 38.3 |
| Purchase and Retirement of Debt | n/a | -57.7 | -57.7 |
| Other Financing Cash Flow | n/a | 0.0 | 0.0 |
| Total Cash From Financing Activities | n/a | -19.4 | -19.4 |
| Exchange Rate Effects | n/a | -0.5 | -0.5 |
| Net Change in Cash | n/a | -557.3 | -557.3 |
| Cash Taxes Paid | n/a | 142.7 | 142.7 |
| Cash Interest Paid | n/a | 17.3 | 17.3 |